2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Bio-Techne Corporation company profile · business segments · history · financial snapshot · S&P 500 rank #484 · Bio-Techne公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | TECH |
| Company | Bio-Techne Corporation |
| GICS sector / industry | Health Care (XLV) / Life Sciences Tools & Services |
| S&P 500 rank (by weight) | #484 · 0.02% (Nov 5, 2026) |
| Sector rank | #57 of 60 in Health Care (Nov 5, 2026) |
| Headquarters | Minneapolis, Minnesota |
| Founded | 1976 |
| CEO | Kim Kelderman (President and Chief Executive Officer) |
| Employees | ~3,000 (as of Jun 30, 2026) |
| Market cap | $11.43B (Nov 5, 2026) |
| SEC filings | EDGAR — CIK 842023 |
WHAT IT DOES
Bio-Techne Corporation develops, manufactures and sells life science reagents, instruments and services for the research, diagnostics and bioprocessing markets. Its Protein Sciences segment supplies the proteins, antibodies, immunoassays and analytical instruments that laboratories use every day, while its Diagnostics and Spatial Biology segment sells regulated diagnostic controls and assays and tissue-based spatial analysis platforms; customers are pharmaceutical and biotechnology companies, academic and government laboratories, diagnostic manufacturers and clinical laboratories. Headquartered in Minneapolis with about 3,000 employees, Bio-Techne has grown largely by acquiring specialist brands and folding them into a single commercial platform. That independent trajectory is now set to end: under the merger agreement signed on June 25, 2026, Merck KGaA would acquire Bio-Techne for $73.00 per share in cash and operate it as a wholly owned subsidiary, which would end Bio-Techne's standalone listing if the merger completes.
BUSINESS SEGMENTS
| Protein Sciences | A leading developer and manufacturer of high-quality biological reagents, including proteins, antibodies and immunoassays, used in life science research, diagnostics and cell and gene therapy, plus proteomic analytical tools for protein analysis, automated western blotting and multiplexed ELISA workflows (brands include R&D Systems, Novus Biologicals and ProteinSimple). FY2026 segment net sales were $874.6M. |
| Diagnostics and Spatial Biology | Develops and manufactures diagnostic products, including controls, calibrators and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridisation assays and instrumentation for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications (brands include Advanced Cell Diagnostics and Lunaphore). FY2026 segment net sales were $336.4M. |
HISTORY
| Year | Milestone |
|---|---|
| 1976 | Founded by Roger C. Lucas in Minneapolis, Minnesota, as Research and Diagnostic Systems, Inc., a maker of hematology controls and calibrators that grew into a broad supplier of biological reagents. |
| 1985 | Merged into Techne Corporation and became a public company; the group operated under the Techne Corporation name for the following three decades. |
| 2014 | Changed its name from Techne Corporation to Bio-Techne in November 2014 and embarked on an acquisition-led expansion, buying Novus Biologicals and ProteinSimple the same year. |
| 2018 | Acquired Exosome Diagnostics for $250 million plus up to $325 million in milestone payments, expanding the diagnostics business into liquid biopsy and exosome-based testing. |
| 2026 | On June 25, 2026, agreed to be acquired by Merck KGaA, Darmstadt, Germany, for $73.00 per share in cash; the FY2026 Form 10-K states the merger is expected to close by late 2026 or early 2027, subject to regulatory and shareholder approvals. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $1.22B (FY2026 revenue) |
| Operating income | $251.9M (FY2026 operating income) |
| Net income | $181.9M (FY2026 net income) |
| Diluted EPS | $1.16 (FY2026 diluted EPS) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Bio-Techne is a small-weight Health Care constituent: rank #484 by weight at 0.02% as of Nov 5, 2026, and #57 in Health Care. It gives the index a specialised life science tools maker, although its agreed acquisition by Merck KGaA would remove it as a standalone constituent if the merger completes.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | Bio-Techne Corporation fiscal 2026 Form 10-K via SEC EDGAR (see Financial Snapshot note); headquarters, CEO and history via the Form 10-K and Wikipedia company profile |
| Index weight & ranks | Slickcharts S&P 500 weights, fetched Nov 5, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS) |
| Market cap | $11.43B (Slickcharts, Nov 5, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | TECH |
| 公司 | Bio-Techne Corporation(Bio-Techne) |
| GICS 板塊/行業 | 健康護理(XLV)/生命科學工具及服務 |
| 標普500排名(按權重) | #484 · 0.02%(Nov 5, 2026) |
| 板塊內排名 | 健康護理板塊 #57(共 60 家)(Nov 5, 2026) |
| 總部 | 美國明尼蘇達州明尼阿波利斯 |
| 成立 | 1976年 |
| 執行長 | Kim Kelderman(總裁兼行政總裁) |
| 員工 | 約 3,000 人(截至 2026 年 6 月 30 日) |
| 市值 | $11.43B(Nov 5, 2026) |
| SEC 申報 | EDGAR — CIK 842023 |
業務概覽
Bio-Techne Corporation 開發、製造及銷售供研究、診斷及生物加工市場使用的生命科學試劑、儀器及服務。其蛋白質科學分部供應實驗室日常使用的蛋白質、抗體、免疫分析試劑及分析儀器;診斷及空間生物學分部則銷售受監管的診斷對照品與檢測,以及組織空間分析平台;客戶包括製藥及生物科技公司、學術及政府實驗室、診斷產品製造商及臨床實驗室。 公司總部位於明尼阿波利斯,僱員約 3,000 人,主要透過收購專門品牌並將其併入單一商業平台而增長。這條獨立發展之路現正走向終點:根據 2026 年 6 月 25 日簽署的合併協議,Merck KGaA 將以每股 73.00 美元現金收購 Bio-Techne,並將其作為全資附屬公司營運;若合併完成,Bio-Techne 的獨立上市地位將告結束。
業務板塊
| 蛋白質科學業務 | 領先的優質生物試劑開發及製造商,產品包括蛋白質、抗體及免疫分析試劑,用於生命科學研究、診斷及細胞與基因治療,並提供用於蛋白質分析、自動化西方墨點法及多重 ELISA 工作流程的蛋白質組學分析工具(品牌包括 R&D Systems、Novus Biologicals 及 ProteinSimple)。2026 財年分部淨銷售額為 8.746 億美元。 |
| 診斷及空間生物學業務 | 開發及製造診斷產品,包括供受監管診斷市場使用的對照品、校準品及診斷檢測,以及用於空間基因組學及組織活檢分析的先進組織原位雜交檢測與儀器,和供研究及臨床應用的遺傳學與腫瘤學試劑盒(品牌包括 Advanced Cell Diagnostics 及 Lunaphore)。2026 財年分部淨銷售額為 3.364 億美元。 |
歷史
| 年份 | 里程碑 |
|---|---|
| 1976 | 由 Roger C. Lucas 在明尼蘇達州明尼阿波利斯創立,初名 Research and Diagnostic Systems, Inc.,最初製造血液學對照品及校準品,其後發展為全面的生物試劑供應商。 |
| 1985 | 併入 Techne Corporation 並成為上市公司;集團其後三十年以 Techne Corporation 之名營運。 |
| 2014 | 於 2014 年 11 月由 Techne Corporation 更名為 Bio-Techne,並展開以收購帶動的擴張,同年收購 Novus Biologicals 及 ProteinSimple。 |
| 2018 | 以 2.50 億美元另加最高 3.25 億美元里程碑付款收購 Exosome Diagnostics,將診斷業務擴展至液體活檢及外泌體檢測。 |
| 2026 | 於 2026 年 6 月 25 日同意由德國達姆施塔特的 Merck KGaA 以每股 73.00 美元現金收購;2026 財年 Form 10-K 表示,合併預計於 2026 年底或 2027 年初完成,尚待監管及股東批准。 |
競爭地位
財務快照
| 總收入 | 12.15 億美元(2026 財年收入) |
| 營業利潤 | 2.52 億美元(2026 財年營業利潤) |
| 淨利潤 | 1.82 億美元(2026 財年淨利潤) |
| 稀釋 EPS | 1.16 美元(2026 財年稀釋 EPS) |
主要風險
對標普500的重要性
Bio-Techne 是權重較小的健康護理板塊成分股:截至 2026 年 11 月 5 日,按權重排名第 484 位,權重 0.02%,在健康護理板塊中排名第 57 位。它為指數帶來一家專門的生命科學工具製造商,惟其已協議由 Merck KGaA 收購,若合併完成,將不再是獨立成分股。
來源與方法
| 財務、板塊、總部 | 財務數據:Bio-Techne Corporation 2026 財年 Form 10-K,經 SEC EDGAR 取得(詳見財務摘要附註);總部、行政總裁及歷史資料來自 Form 10-K 及 Wikipedia 公司簡介 |
| 指數權重與排名 | Slickcharts 標普 500 權重,Nov 5, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS) |
| 市值 | $11.43B(Slickcharts,Nov 5, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-04 14:43 · updated 2026-11-15 00:06 · rev 9